GlassScriptPhysician profile
Stephanie Willis
NPI 1720616873
$1,773.33
in general payments reported to CMS, 2019-2025
22 companies · $396 in 2025
The $396 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $87.36 · 2022: $262 · 2023: $488 · 2024: $540 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,424.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $416.65 | 2022-2025 | |
| Sanofi Pasteur INC. | $252.72 | 2023-2025 | |
| Phadia US INC. | $163.49 | 2023-2025 | Immunocap |
| Cranial Technologies, INC | $135.64 | 2021-2023 | Doc Band |
| Cognoa, INC. | $123.23 | 2022 | |
| Merck Sharp & Dohme LLC | $122.84 | 2023-2024 | Gardasil, Gardasil 9, Vaxelis |
| Lilly USA, LLC | $98.01 | 2022-2024 | Jardiance, Emgality |
| Ironshore Pharmaceuticals INC. | $60.62 | 2023-2024 | Jornay Pm |
| Biohaven Pharmaceutical Holding Company LTD. | $48.68 | 2022 | |
| Medtronic, INC. | $45.04 | 2022 | |
| Amgen INC. | $43.29 | 2023-2024 | Repatha, Otezla |
| Novo Nordisk INC | $42.84 | 2023-2024 | Wegovy |
| Glaxosmithkline, LLC. | $32.61 | 2024-2025 | Bexsero |
| Neurelis, INC. | $28.37 | 2025 | Valtoco |
| Ars Pharmaceuticals Operations, INC. | $25.73 | 2025 | Neffy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.24 | 2025 | Caplyta |
| Corium, LLC | $21.23 | 2025 | Azstarys |
| Soleno Therapeutics, INC. | $20.01 | 2025 | Vykat Xr |
| Idorsia Pharmaceuticals US INC | $19.54 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $16.58 | 2023 | Fasenra |
| Dexcom, INC. | $16.30 | 2023 | Dexcom G6 Transmitter |
| Harmony Biosciences LLC | $15.67 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.